Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05393180 · ClinicalTrials.gov registry record · NA
CONVERGE Post-Approval Study (PAS)
A NA study of Chronic Atrial Fibrillation, sponsored by AtriCure.
- Active
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 13
- Study locations
NCT05393180 is a NA study of Chronic Atrial Fibrillation that is active but no longer recruiting, run by AtriCure. The registered enrollment target is 53 participants. The trial reports 13 study locations across 11 states.
The verdict
NCT05393180, a NA study of Chronic Atrial Fibrillation, is active but no longer recruiting, sponsored by AtriCure.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Conditions Studied
Interventions
- DEVICE Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF
Study Locations (13)
Florida
- Baycare Health Systems - Clearwater
- Orlando Health - Orlando
Georgia
- Emory Saint Joseph Hopsital - Atlanta
- Wellstar Health System - Marietta
California
- Sutter Bay Hospitals - San Francisco
Connecticut
- Hartford Hospital - Hartford
Kentucky
- Norton Heart & Vascular Institute - Louisville
Maryland
- MedStar Union Memorial Hospital - Baltimore
Massachusetts
- Southcoast Hospitals Group - New Bedford
New Jersey
- AtlantiCare Medical Center - Atlantic City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2029-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05393180
The ClinicalTrials.gov registry entry for NCT05393180 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AtriCure, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF is the first listed.
NCT05393180 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Florida, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT05393180 about?
NCT05393180 is a clinical study titled "CONVERGE Post-Approval Study (PAS)". The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillati...
What is the current status of trial NCT05393180?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2022-04-13. Estimated completion is 2029-01-01.
What conditions does trial NCT05393180 study?
This clinical trial studies the following conditions: Chronic Atrial Fibrillation.
What interventions are being tested in trial NCT05393180?
The interventions under investigation include: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF (DEVICE).
Who is sponsoring clinical trial NCT05393180?
This trial is sponsored by AtriCure, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05393180 being conducted?
This trial has 13 study locations across California, Connecticut, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.